Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2016
At a glance
- Drugs Tavokinogene telsaplasmid (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors OncoSec Medical
- 10 Jun 2017 Biomarkers information updated
- 12 Dec 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Mar 2017.
- 03 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.